398 related articles for article (PubMed ID: 24627612)
1. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
Prasad K
Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
[TBL] [Abstract][Full Text] [Related]
2. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
[TBL] [Abstract][Full Text] [Related]
3. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
4. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
6. Advanced Glycation End Products and its Soluble Receptors in the Pathogenesis of Thoracic Aortic Aneurysm.
Prasad K; Sarkar A; Zafar MA; Shoker A; Moselhi HE; Tranquilli M; Ziganshin BA; Elefteriades JA
Aorta (Stamford); 2016 Feb; 4(1):1-10. PubMed ID: 27766267
[TBL] [Abstract][Full Text] [Related]
7. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
9. AGE-RAGE Stress and Coronary Artery Disease.
Prasad K
Int J Angiol; 2021 Mar; 30(1):4-14. PubMed ID: 34025091
[TBL] [Abstract][Full Text] [Related]
10. Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.
Prasad K; Dhar I; Caspar-Bell G
Int J Angiol; 2015 Jun; 24(2):75-80. PubMed ID: 26060376
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
[TBL] [Abstract][Full Text] [Related]
12. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
Saito R; Araki S; Yamamoto Y; Kusuhara K
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
[TBL] [Abstract][Full Text] [Related]
13. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
17. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
18. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
19. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
20. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study.
Heier M; Margeirsdottir HD; Gaarder M; Stensæth KH; Brunborg C; Torjesen PA; Seljeflot I; Hanssen KF; Dahl-Jørgensen K
Cardiovasc Diabetol; 2015 Sep; 14():126. PubMed ID: 26408307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
